Psoralen Suppresses Cisplatin-Mediated Resistance and Induces Apoptosis of Gastric Adenocarcinoma by Disruption of the miR196a-HOXB7-HER2 Axis.
HOXB7
chemoresistance
cisplatin
gastric cancer
miR-196a-5p
psoralen
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
02
2020
accepted:
02
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
The present study aimed to investigate the impact of psoralen on miR-196a-5p expression and function, and to reveal the mechanism underlying miR-196a-5p-mediated inhibition and the reversal of cisplatin (DDP) resistance. Serum samples were collected from 50 patients with gastric cancer (GC), and the association between miR-196a-5p expression and the response to chemotherapy was assessed. A DDP-resistant GC cell line was also established to determine the effects of miR-196a-5p and psoralen on DDP resistance. MGC803 cells were transfected with miR-196a-5p mimic and inhibitor vectors for the overexpression and downregulation of miR-196a-5p, respectively. Clinical data analysis showed that the lower expression levels of miR-196a-5p were significantly associated with chemoresistance in patients with GC. Upregulation of miR-196a-5p significantly enhanced the anti-proliferative effect, apoptosis and sensitivity to DDP by regulating the protein expression levels of HOXB7, HER2, Bcl-2 and G miR-196a-5p may be a novel biomarker of chemotherapeutic success in patients with GC and may also influence the sensitivity of GC cells to DDP. Moreover, psoralen can increase chemotherapeutic sensitivity by upregulating miR-196a-5p and then downregulating HOXB7-HER2 signaling axis.
Identifiants
pubmed: 32368152
doi: 10.2147/CMAR.S248094
pii: 248094
pmc: PMC7185648
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2803-2827Informations de copyright
© 2020 Jin et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Clin Cancer Res. 2017 Sep 1;23(17):5255-5266
pubmed: 28533224
J Natl Cancer Inst. 2015 Feb 06;107(3):
pubmed: 25663689
Cancer Res. 2008 Jan 15;68(2):425-33
pubmed: 18199536
Nat Commun. 2016 Aug 03;7:12351
pubmed: 27484502
DNA Cell Biol. 2007 May;26(5):293-300
pubmed: 17504025
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Oral Oncol. 2010 Apr;46(4):317-22
pubmed: 20219416
AJR Am J Roentgenol. 2004 Dec;183(6):1619-28
pubmed: 15547201
Oncotarget. 2017 Aug 3;8(39):66226-66236
pubmed: 29029506
Toxicology. 2013 Apr 5;306:162-8
pubmed: 23466500
Blood. 2017 Apr 27;129(17):2408-2419
pubmed: 28188132
J Exp Zool B Mol Dev Evol. 2005 Jan 15;304(1):75-85
pubmed: 15643628
Circ Res. 2017 Jan 6;120(1):85-98
pubmed: 27756792
Nature. 2015 Nov 5;527(7576):100-104
pubmed: 26479035
Lancet Oncol. 2015 Jul;16(7):804-15
pubmed: 26088272
Iran J Basic Med Sci. 2018 Apr;21(4):427-433
pubmed: 29796229
Nat Commun. 2016 Apr 04;7:11169
pubmed: 27041221
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
Gut. 2015 Dec;64(12):1881-8
pubmed: 25748648
Tumour Biol. 2016 Feb;37(2):2387-94
pubmed: 26376998
Oncotarget. 2016 May 31;7(22):33202-9
pubmed: 27120805
Mol Cancer. 2018 Apr 23;17(1):83
pubmed: 29685157
Lancet. 2015 Feb 26;385 Suppl 1:S100
pubmed: 26312830
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
PLoS One. 2014 Feb 14;9(2):e88983
pubmed: 24551203
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Oncol Rep. 2017 Oct;38(4):2148-2154
pubmed: 28791406
Chin Med. 2010 Jul 25;5:26
pubmed: 20653978
Arch Dermatol. 2003 Jun;139(6):771-5
pubmed: 12810509
Cancer Res. 2015 Jun 1;75(11):2400
pubmed: 25977339
Chin Med J (Engl). 1992 Dec;105(12):1026-8
pubmed: 1299551
Iran Red Crescent Med J. 2013 Feb;15(2):101-6
pubmed: 24693415
Cell Mol Life Sci. 2010 Oct;67(20):3535-48
pubmed: 20480203
Lancet Oncol. 2010 Feb;11(2):136-46
pubmed: 20022810
Mol Cancer. 2015 Nov 17;14:196
pubmed: 26576679
Cancer Cell. 2014 Apr 14;25(4):469-83
pubmed: 24735923
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
J Natl Cancer Inst. 2013 Jun 19;105(12):849-59
pubmed: 23704278
Biochem Biophys Res Commun. 2009 Jun 5;383(3):280-5
pubmed: 19302977
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8
pubmed: 15194824
Expert Rev Mol Diagn. 2011 Apr;11(3):249-57
pubmed: 21463235
Semin Radiat Oncol. 2002 Apr;12(2):150-61
pubmed: 11979416
Nature. 2014 Aug 28;512(7515):431-5
pubmed: 25043055
Cancer Prev Res (Phila). 2017 Jun;10(6):337-344
pubmed: 28465362
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
J Clin Oncol. 2013 Aug 10;31(23):2903-11
pubmed: 23835716
Dev Biol. 2009 Oct 15;334(2):468-80
pubmed: 19682983
Nutr Res. 2014 Jul;34(7):585-94
pubmed: 25150117
Oncotarget. 2016 Sep 6;7(36):58595-58605
pubmed: 27517632
Arch Dermatol. 2005 Mar;141(3):305-11
pubmed: 15781671
Gynecol Oncol. 2008 Dec;111(3):478-86
pubmed: 18823650
Tumour Biol. 2014 Feb;35(2):1287-95
pubmed: 24068565
Dig Dis Sci. 2010 Sep;55(9):2545-51
pubmed: 19960259
Oncotarget. 2017 Jan 3;8(1):1247-1261
pubmed: 27901487
Lancet. 2012 Jan 28;379(9813):315-21
pubmed: 22226517
J Clin Oncol. 2010 Apr 1;28(10):1721-6
pubmed: 20194856
Crit Rev Oncol Hematol. 2012 Feb;81(2):103-22
pubmed: 21546262
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Cancer Discov. 2015 Sep;5(9):944-59
pubmed: 26180042
Lancet. 2016 Nov 26;388(10060):2606
pubmed: 27894662
Mol Cancer Ther. 2008 Jul;7(7):2152-9
pubmed: 18645025
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Mol Cells. 2018 May 31;41(5):390-400
pubmed: 29754469
Int J Cancer. 2008 Jul 15;123(2):372-379
pubmed: 18449891
Asian Pac J Cancer Prev. 2015;16(5):1781-7
pubmed: 25773825